Dianthus Therapeutics, Inc. (DNTH) Cash Flow Statement

The OCF/NI ratio near 1.0 in most quarters indicates that reported losses are largely cash-based, with minimal accrual distortion. However, the 2025Q4 net income spike to $97.9M, likely from a non-cash item, creates a temporary divergence where OCF remained negative at -$47.0M. This suggests that investors should focus on operating cash flow rather than net income to gauge the true cash consumption of the clinical programs.

The FCF margin, though distorted by minimal revenue, has become more negative over time, with the quarterly burn nearly tripling in two years. This trajectory indicates that the company is in a heavy investment phase, and the lack of revenue growth means the burn will likely continue until clinical milestones are reached. The widening gap between FCF and net income in 2025Q4 highlights the need to strip out non-cash items to assess the sustainable cash outflow.

The extremely low capital intensity is typical of a clinical-stage biotech that does not own manufacturing facilities. This suggests that the primary cash burn is driven by R&D and G&A expenses rather than fixed asset investments. As the company approaches commercialization, capex may rise, but for now, the asset-light model keeps capital requirements focused on operational expenses.

The positive working capital changes in 2025Q4 and 2026Q1 suggest that the company is managing payables and receivables to conserve cash, possibly delaying payments to vendors. However, the negative swing in 2026Q2 indicates a reversal, which may be due to accelerated trial-related expenses. These fluctuations are not indicative of operational efficiency but rather the lumpy nature of clinical trial cash flows.

The absence of shareholder returns is expected for a clinical-stage company, but the small buyback in 2025Q4 is unusual and may be related to merger-related activities. The focus on pipeline investment is clear, but with only $51M in cash and a quarterly burn of ~$49M, the company may need to raise capital soon, which could dilute existing shareholders.

The cumulative divergence between net income and operating cash flow is significant, with OCF being more negative than net income in most periods. This suggests that non-cash items, such as the 2025Q4 gain, have inflated net income relative to cash burn. Investors should rely on operating cash flow as the more accurate measure of cash consumption, as the gap may widen further with continued trial expansion.